Compound for inhibiting and degrading irak4, and pharmaceutical composition and pharmaceutical application thereof

A compound or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof, wherein the compound is a compound represented by general formula (I),

• B-L-K (I);
• L is selected from -Ak1-Cy1-Ak2-Cy2-Ak3-Cy3-Ak4-Cy4-Ak5-;
• Ak1, Ak2, Ak3, Ak4 and Ak5 are each independently selected from —(CH2)q—, O, —(CH2)qNRL—, NRLC═O, C═ONRL, C═O, —RLC═CRL, C═C or a bond;
• RL is selected from H or C1-6 alkyl;
• Cy1, Cy2, Cy3 and Cy4 are each independently selected from a bond, 4- to 7-membered mono-heterocyclic ring, 4- to 10-membered fused-heterocyclic ring, 5- to 12-membered spiro-heterocyclic ring, 7- to 10-membered bridged-heterocyclic ring, 3- to 7-membered monocycloalkyl, 4- to 10-membered fused cycloalkyl, 5- to 12-membered spiro cycloalkyl, 7- to 10-membered bridged cycloalkyl, 5- to 10-membered heteroaryl or 6- to 10-membered aryl, wherein the aryl, heteroaryl, cycloalkyl, mono-heterocyclic ring, fused-heterocyclic ring, spiro-heterocyclic ring or bridged-heterocyclic ring is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, C(═O)OH, CN, NH2, ═O, C1-4 alkyl, halogen-substituted C1-4 alkyl, hydroxyl-substituted C1-4 alkyl or C1-4 alkoxy, and the heteroaryl, mono-heterocyclic ring, fused-heterocyclic ring, spiro-heterocyclic ring or bridged-heterocyclic ring contains 1 to 4 heteroatoms selected from O, S, or N;
• B is selected from
• B1 and B3 are each independently selected from C6-10 aryl, 5- to 10-membered heteroaryl or 4- to 10-membered heterocyclyl, wherein the heteroaryl or heterocyclyl contains 1 to 4 heteroatoms selected from O, S or N;
• Rb1 and Rb7 are each independently selected from H, F, Cl, Br, I, ═O, OH, NH2, CN, CF3, C(—O) OH, CHF2, C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, —(CH2)n—Rb21, —ORb21, —N(Rb21)2, C6-10 aryl, 5- to 10-membered heteroaryl or 4- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, ═O, —N(Rb21)2, CN, CF3, C(═O)OH, C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocyclyl or Rb7a, and the heteroaryl or heterocyclyl contains 1 to 4 heteroatoms selected from O, S, or N;
• Rb7a is selected from C1-4 alkyl, —C3-6 cycloalkyl, 4- to 10-membered heterocyclyl, —C1-4 alkylene-C3-6 cycloalkyl, —C1-4 alkylene 4- to 10-membered heterocyclyl, —O—C3-6 cycloalkyl, —O-4- to 10-membered heterocyclyl, —NH—C3-6 cycloalkyl, —NH-4- to 10-membered heterocyclyl, —N(C1-4 alkyl)-C3-6 cycloalkyl or —N(C1-4 alkyl)-4- to 10-membered heterocyclyl, wherein the Rb7a is optionally substituted with 1 to 4 substituents selected from H, F, Cl, Br, I, OH, —O, —N(Rb21)2, CN, CF3, C(═O)OH, C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl or 4- to 10-membered heterocyclyl, and the heterocyclyl contains 1 to 4 heteroatoms selected from O, S, or N;
• Rb2 and Rb6 are each independently selected from H, F, Cl, Br, I, ═O, OH, —C(═O)N(Rb21)2, —N(Rb21)2, CN, CF3, C(═O)OH, CHF2, C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, —(CH2)n—Rb21, —ORb21, C6-10 aryl, 5- to 10-membered heteroaryl or 4- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, cycloalkyl, aryl, heteroaryl or heterocyclyl is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, ═O, NH2, CN, CF3, C(═O)OH, C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, 5- to 10-membered heteroaryl or 4- to 10-membered heterocyclyl, and the heteroaryl or heterocyclyl contains 1 to 4 heteroatoms selected from O, S, or N;
• each Rb21 is independently selected from H, C1-6 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, C6-10 aryl, 5- to 10-membered heteroaryl or 4- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, cycloalkyl, aryl, heteroaryl or heterocyclyl is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, ═O, NH2, CN, CF3, C(═O)OH, C1-4 alkyl, C3-6 cycloalkyl or C1-4 alkoxy, and the heteroaryl or heterocyclyl contains 1 to 4 heteroatoms selected from O, S, or N;
• n is selected from 0, 1, 2, 3 or 4;
• K is selected from
• each Rk1 is independently selected from H, C1-4 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or 3- to 6-membered heterocycloalkyl, wherein the alkyl, cycloalkyl or heterocycloalkyl is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, NH2, CN, CF3, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl or C3-6 cycloalkyl;
• Rk2 and Rk3 are each independently selected from H, F, Cl, Br, I, OH, ═O, NH2, CF3, CN, C(═O)OH, C(═O)NH2, C1-4 alkyl or C1-4 alkoxy, wherein the alkyl or alkoxy is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, or NH2;
• or two Rk3 together with the carbon atoms or ring backbones to which they are directly attached form 3- to 6-membered carbocycle or 3- to 7-membered heterocycle, wherein the carbocycle or heterocycle is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, ═O, NH2, CN, C(═O)OH, C(═O)NH2, C1-4 alkyl or C1-4 alkoxy, and the heterocycle contains 1 to 4 heteroatoms selected from O, S or N;
• q is selected from 0, 1, 2, 3 or 4;
• n1, n2 and n6 are each independently selected from 0, 1, 2 or 3;
• p2 and p3 are each independently selected from 0, 1, 2, 3 or 4;
• optionally, 0 to 50 H of the compound represented by general formula (I) are replaced by 0 to 50 D.